Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2016

01-10-2016 | Original Article

The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines

Authors: Ismael Riquelme, Oscar Tapia, Jaime A. Espinoza, Pamela Leal, Kurt Buchegger, Alejandra Sandoval, Carolina Bizama, Juan Carlos Araya, Richard M. Peek, Juan Carlos Roa

Published in: Pathology & Oncology Research | Issue 4/2016

Login to get access

Abstract

The PI3K/AKT/mTOR pathway plays a crucial role in the regulation of multiple cellular functions including cell growth, proliferation, metabolism and angiogenesis. Emerging evidence has shown that deregulation of this pathway has a role promoting gastric cancer (GC). The aim was to assess the expression of genes involved in this pathway by qPCR in 23 tumor and 23 non-tumor gastric mucosa samples from advanced GC patients, and in AGS, MKN28 and MKN45 gastric cancer cell lines. Results showed a slight overexpression of PIK3CA, PIK3CB, AKT1, MTOR, RPS6KB1, EIF4EBP1 and EIF4E genes, and a slightly decreased PTEN and TSC1 expression. In AGS, MKN28 and MKN45 cells a significant gene overexpression of PIK3CA, PIK3CB, AKT1, MTOR, RPS6KB1 and EIF4E, and a significant repression of PTEN gene expression were observed. Immunoblotting showed that PI3K-β, AKT, p-AKT, PTEN, mTOR, p-mTOR, P70S6K1, p-P70S6K1, 4E-BP1, p-4E-BP1, eIF4E and p-eIF4E proteins were present in cell lines at different levels, confirming activation of this pathway in vitro. This is the first time this extensive panel of 9 genes within PI3K/AKT/mTOR pathway has been studied in GC to clarify the biological role of this pathway in GC and develop new strategies for this malignancy.
Literature
1.
2.
Brenner H, Rothenbacher D, Arndt V (2009) Epidemiology of stomach cancer. Methods Mol Biol 472:467–477CrossRefPubMed
3.
4.
5.
Zhang W (2014) TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chin J Cancer 33:469–470PubMedPubMedCentral
6.
Al-Batran S-E, Ducreux M, Ohtsu A (2012) mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 130:491–496CrossRefPubMed
7.
Fan Q-W, Weiss WA (2010) Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 347:279–296PubMedPubMedCentral
8.
Matsuoka T, Yashiro M (2014) The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel) 6:1441–1463CrossRef
9.
Yang W, Raufi A, Klempner SJ (2014) Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta 1846:232–237PubMed
10.
Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs 16:797–803CrossRefPubMed
11.
12.
Polivka J, Janku F (2014) Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142:164–175CrossRefPubMed
13.
Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, et al. (2014) The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch 465:25–33CrossRefPubMed
14.
Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8:393–412CrossRefPubMed
15.
16.
17.
Dreesen O, Brivanlou AH (2007) Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3:7–17CrossRefPubMed
18.
Xiao L, Wang YC, Li WS, Du Y (2009) The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28:152CrossRefPubMedPubMedCentral
19.
Chen H, Guan R, Lei Y, Chen J, Ge Q, et al. (2015) Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer 15:103CrossRefPubMedPubMedCentral
20.
Greenfield LK, Jones NL (2013) Modulation of autophagy by helicobacter pylori and its role in gastric carcinogenesis. Trends Microbiol 21:602–612CrossRefPubMed
21.
Liu JF, Zhou XK, Chen JH, Yi G, Chen HG, et al. (2010) Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol 16:4986–4991CrossRefPubMedPubMedCentral
22.
Ye B, Jiang L-L, Xu H-T, Zhou D-W, Li Z-S Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol 25:627–636
23.
Cinti C, Vindigni C, Zamparelli A, La Sala D, Epistolato MC, et al. (2008) Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch 453:449–455CrossRefPubMed
24.
Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, et al. (2009) Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 100:782–788CrossRefPubMedPubMedCentral
25.
Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, et al. (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803–1810CrossRefPubMed
26.
Sun DF, jie ZY, XQ T, YX C, JY F (2014) Inhibition of mTOR signalling potentiates the effects of trichostatin a in human gastric cancer cell lines by promoting histone acetylation. Cell Biol Int 38:50–63CrossRefPubMed
27.
Yang HY, Xue LY, Xing LX, Wang J, Wang JL, et al. (2013) Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma. Mol Med Rep 7:537–542PubMed
28.
Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun S-Y (2014) Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 8:1463–1469CrossRef
29.
Liang S, Guo R, Zhang Z, Liu D, Xu H, et al. (2013) Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. Oncol Rep 29:2422–2430PubMed
30.
Chen C-N, Hsieh F-J, Cheng Y-M, Lee P-H, Chang K-J (2004) Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol 86:22–27CrossRefPubMed
31.
Wen Y-G, Wang Q, Zhou C-Z, Qiu G-Q, Peng Z-H, Tang H-M (2010) Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 24:89–95PubMed
32.
Kang Y-H, Lee HS, Kim WH (2002) Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Investig 82:285–291CrossRefPubMed
33.
Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, et al. (2011) Global quantification of mammalian gene expression control. Nature 473:337–342CrossRefPubMed
34.
The Cancer Genome Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202–209CrossRef
Metadata
Title
The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines
Authors
Ismael Riquelme
Oscar Tapia
Jaime A. Espinoza
Pamela Leal
Kurt Buchegger
Alejandra Sandoval
Carolina Bizama
Juan Carlos Araya
Richard M. Peek
Juan Carlos Roa
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0066-5

Other articles of this Issue 4/2016

Pathology & Oncology Research 4/2016 Go to the issue

Original Article

Detection of Merkel Cell Polyomavirus and Human Papillomavirus in Esophageal Squamous Cell Carcinomas and Non-Cancerous Esophageal Samples in Northern Iran

Original Article

Strong Correlation Between mRNA Expression Levels of HIF-2α, VEGFR1, VEGFR2 and MMP2 in Laryngeal Carcinoma

Original Article

The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients

Original Article

Aberrant Expression of Calretinin, D2–40 and Mesothelin in Mucinous and Non-Mucinous Colorectal Carcinomas and Relation to Clinicopathological Features and Prognosis

Original Article

Immunohistochemical Study EMT-Related Proteins in HPV-, and EBV-Negative Patients with Sinonasal Tumours

Original Article

Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits